mutual funds

Primecap Odyssey Growth Has a Rough Year

The fund trailed the S&P by a wide margin, but over the long haul Primecap's managers have not disappointed shareholders.

The managers at Primecap Oydssey Growth (POGRX) like to focus on what they do best – pick stocks – and they typically don't talk to reporters.

So once a year, when the fund's annual report comes out, we read every word. Over the past 12 months, Kiplinger 25 member Odyssey Growth gained 12.7%, which trailed the 24.7% gain in the S&P 500.

We're not worried. Short-term returns can be instructive and add some perspective, but long-term performance matters most.

And over the long haul, Primecap's managers have not disappointed shareholders. The fund's 15-year annualized return, 11.3%, beat the S&P 500 by an average of 0.7 percentage point per year.

But 2021 was a win-some, lose-some year for the fund. Some of the fund's top 10 holdings generated market-beating returns. Shares in banking giant Morgan Stanley (MS), for instance, gained 42% over the past 12 months. Other top holdings jumped even higher: Eli Lilly (LLY) was up 59%; Alphabet (GOOGL), 54%; and Microsoft (MSFT), 45%.

Biotech Stocks Stumble

But the fund holds 15% of assets in biotech stocks – a chunk, relative to the 2% exposure in the S&P 500 – which pressured results.

Biotechnology was the worst-performing slice of the health industry over the past 12 months, thanks in part to drug-pricing concerns and regulatory issues.

Epizyme (EPZM) dropped 81% over the past 12 months after an "anemic" new drug launch, the Primecap managers reported. And FibroGen (FGEN) stumbled, too, losing 66% after clinical missteps and regulatory setbacks.

China proved to be a snag as well. The fund has a significant stake in Alibaba (BABA), the Amazon of China, and the stock slipped 43% over the past 12 months because of increased government scrutiny.

The fund's five managers divide and run a portion of the fund’s assets independently. But they all favor stocks in fast-growing firms with long-term growth potential that they think the market has underestimated. When they buy, they tend to hold. The fund's 7% turnover implies a typical holding period of more than a decade. They're patient and willing to wait for their investment thesis to play out. We'll wait with them.

Most Popular

What Are the Income Tax Brackets for 2022 vs. 2021?
tax brackets

What Are the Income Tax Brackets for 2022 vs. 2021?

Depending on your taxable income, you can end up in one of seven different federal income tax brackets – each with its own marginal tax rate.
September 20, 2022
Your Guide to Roth Conversions
Special Report
Tax Breaks

Your Guide to Roth Conversions

A Kiplinger Special Report
February 25, 2021
19 Best Stocks to Buy Now for High Upside Potential
stocks

19 Best Stocks to Buy Now for High Upside Potential

Finding the best stocks to buy when the market is selling off can be daunting, but the pros believe these 19 top-rated names are poised for big return…
September 23, 2022

Recommended

3 Bond Funds to Build on a Summer Rally
bonds

3 Bond Funds to Build on a Summer Rally

The market expects consistently lower inflation to arrive sooner rather than later. That's great news for these three bond funds.
August 31, 2022
Don't Give Up on the Eurozone
mutual funds

Don't Give Up on the Eurozone

As Europe’s economy (and stock markets) wobble, Janus Henderson European Focus Fund (HFETX) keeps its footing with a focus on large Europe-based multi…
August 30, 2022
5 Fantastic Actively Managed Fidelity Funds to Buy
mutual funds

5 Fantastic Actively Managed Fidelity Funds to Buy

In a stock picker's market, it's sometimes best to leave the driving to the pros. These Fidelity funds provide investors solid active management at lo…
August 4, 2022
How to Invest for a Recession
investing

How to Invest for a Recession

During a recession, dividends are especially important because they give you a cushion even if the stock price falls.
August 1, 2022